Refractory Transformed Non-Hodgkin Lymphoma Clinical Trials

9 clinical trials for Refractory Transformed Non-Hodgkin Lymphoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome — RECRUITING · PHASE2
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy — RECRUITING · PHASE2
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. — ACTIVE_NOT_RECRUITING · PHASE1
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma — OTHER · PHASE1
• Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL — TERMINATED · PHASE2

Refine this search